Mr. Ken Powell
President, Genesis Business Development, LLC
Member of the Healthcare Council
Council Member Biography
Ken Powell is the President of Genesis Business Development, a health care consultancy. Mr. Powell has experience in the identification, acquisition, and commercialization of new businesses and products in the clinical diagnostics, life sciences and medical device market segments. He has provided international Expert Witness Testimony. Mr. Powell is knowledgeable about emerging technologies, M&A, personalized medicine, molecular diagnostics, "next-gen" sequencing, hospital, commercial reference, physician lab and OTC segments, clinical lab systems, point-of-care, genomics, life sciences, distributors and medical devices. Mr. Powell is also knowledgeable about evolving regulatory and reimbursement issues. He has held senior management positions with Becton Dickinson, Roche Diagnostics, Technicon, Armour Pharmaceuticals, and Upjohn Clinical Laboratory Procedures. Mr. Powell is conversant in all aspects of clinical diagnostics, life sciences segments, public and private companies. (This is me - Update Profile)
Employment History
- 2006 - Unspecified
- President, Genesis Business Development, LLC
- 1986 - 2006
- Director of Business Development, BECTON, DICKINSON AND COMPANY
- 1984 - 1986
- Director of Marketing, Revlon Healthcare
- 1982 - 1983
- Senior Product Manager, Becton Dickinson Immunodiagnostics
- 1976 - 1982
- Product Manager, ROCHE DIAGNOSTICS CORPORATION
- 1975 - 1976
- Sales Representative, Upjohn Laboratory Procedures, PHARMACIA & UPJOHN, INC.
GLG NewsSM Analyses by Ken Powell
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
February 7, 2012
Several emerging trends could impact commercial reference lab revenue. They include developments in pre-certification programs, molecular diagnostic and Laboratory Developed Test (LDT) registries, reimbursement programs and codes and test formularies.
-
New competitor enters ovarian cancer test market
January 26, 2012
Laboratory Corporation of America Holdings (LabCorp ) announced the launch of its FDA-cleared risk stratification tool that aids in the diagnosis of ovarian masses prior to planned surgeries. This new test could be a competitor to Vermillion’s OVA1 which is marketed by partner Quest Diagnostics.
-
Trends in physician office practices
January 17, 2012
American Hospital Association statistics show that the number of physicians employed by hospitals has grown 32% since 2000. In-office lab testing continues to be strong revenue source for doctors faced with decreasing reimbursement rates. Mobile connectivity continues to thrive.
-
Clinical diagnostic acquisitions dominate 2011 top ten list
January 12, 2012
Top ten medical device deals of 2011 | www.fiercemedicaldevices.com
Four of the top ten medical device deals in 2011 involved clinical diagnostic companies. Diagnostic test results have been reported as responsible for over 70% of clinical decisions, so look for continued consolidation in this space in 2012.
-
New competitor plans to enter high growth HPV market
December 8, 2011
San Jose, Calif.-based OncoHealth plans to enter the high growth Human papillomavirus (HPV) market with a new test. Oncohealth says the assay, to be marketed under the name Oncohealth Direct E6/E7, offers higher specificity than DNA-based HPV assays. Also it's important to note that the assay’s ELISA technology utilizes readily available immunoassay equipment that does not require expensive molecular diagnostic equipment or personnel to perform the test. This makes it more convenient than DNA-based assays.
GLG Study Groups with Ken Powell(?)
| Study Group Name | No. Members |
|---|---|
| Economic Experts on Managed Care | 804 |
| Medical Device Experts | 513 |
| Mass Spectrometry Products Experts | 100 |
| Pricing Experts on Clinical Lab Testing in the U.S. | 58 |
| Illumina's SNP Chip Users (US) | 41 |
GLG Live Meetings with Ken Powell(?)
Ken Powell has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.